期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 22, 期 11, 页码 1915-1925出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2016.07.013
关键词
Hematopoietic cell transplantation; Busulfan; Precision medicine; Pharmacokinetics; Therapeutic drug monitoring
资金
- National Cancer Institute [CM 82963]
The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This Considerations document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians. (C) 2016 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据